Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Baucus: 'Effectiveness' Part Of Health-Care Bill, Could Reduce Health Costs
"Senate Finance Chairman Max Baucus, D-Mont., said Tuesday he expects Senate health-care legislation will include provisions encouraging doctors to compare drugs and therapies for their effectiveness," Dow Jones Newswires reports. At a conference at the Brookings Institution, "Baucus said he plans to re-introduce legislation with Sen. Kent Conrad, D-N.D., that further boosts" comparative effectiveness research. The research, which "saw $1.1 billion from the federal stimulus package earlier this year," lets "doctors and patients to utilize publicly-available information on medical treatments, has emerged as something of a political lightning rod this year. Some conservative Republicans are suggesting it would result in rationing of health care." But Baucus "sought to dispel that notion Tuesday, saying that the research would not be used solely to cut costs" (Yoest, 6/9).
generic viagra online
Giving Early Physical And Occupational Therapy To Critically Ill Patients Leads To Better Outcomes
Long-term complications of critical illness include intensive care unit (ICU)-acquired weakness and neuropsychiatric disease - both of which could be related to the immobilisation caused by sedation. An Article published Online First and in an upcoming edition of The Lancet has found that interrupting sedation in the earliest days of treatment to give critically ill patients physical and occupational therapy leads to better outcomes than standard care.
News of the day
CytRx's Tamibarotene Receives Positive Opinion From The Committee For Orphan Medicinal Products In The European Union For Treatment Of APL
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of acute promyelocytic leukemia (APL). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the community register. This favorable opinion for tamibarotene in the European Union (EU) is in addition to the Orphan Drug Designation for APL and Fast Track Designation for the treatment of adult patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide granted by the U.S. Food and Drug Administration (FDA) in October 2007.
Health Insurance

Certain Research Could Remain Limited Under New Stem Cell Rules, New York Times Editorial States

The "good news" about the Obama administration"s final guidelines for federally funded embryonic stem cell research is that "government money will pay for a lot more research than was possible under the Bush administration"s cramped and ideologically driven restrictions," according to a New York Times editorial. However, "some of the most promising future research could still be denied public support," the editorial continues.Under former President George W. Bush, federal funding for embryonic stem cell research was limited "to a mere 21 lines that had been derived with private money from surplus embryos at fertility clinics before mid-2001," the editorial states. The new guidelines allow scientists "to use new stem cell lines provided they come from surplus fertility embryos that were donated under strict ethical rules," according to the editorial. It adds, "Those rules stipulate that donors must be fully informed that any embryo donated for research would be destroyed in the process and that there are other choices for disposing of surplus embryos." In addition, donors must "give written consent at the time of donation, have the right to change their minds and must not receive payment for the donation or expect medical or financial benefits later," the editorial notes.The editorial continues that NIH, "[f]earing controversy, ... decided to deny support to research using lines that might eventually be created in the laboratory by "therapeutic cloning" to match specific patients with specific diseases." It adds, "Such cells could provide a valuable way to study the early stages of a disease and to derive stem cell implants that would not be rejected by a patient"s immune system." The editorial states that NIH officials argued that scientists have yet to successfully derive human embryonic stem cells from therapeutic cloning and that "there is no strong public sentiment for moving beyond the use of surplus embryos that would otherwise be discarded." The editorial concludes, "The agency will need to reconsider those judgments as science and ethical thinking evolves. For now, the administration seems determined to follow congressional and public opinion rather than lead it" (New York Times, 7/8). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009